Calvin J. Cohen - Articles and news items

Bristol Myers Squibb logo

Bristol-Myers Squibb submits new drug application to FDA for a fixed-dose combination of atazanavir sulfate with cobicistat for HIV-1

Industry news / 14 April 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced the submission of a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate…

Gilead logo

Gilead ’s Complera® non-inferior to Atripla® among treatment-naïve HIV patients

Industry news, News / 15 November 2012 / Gilead Sciences

STaR study findings support Complera as an important single tablet regimen option…

Janssen Pharmaceuticals Logo

Edurant™ 96-Week Phase 3 safety and efficacy data presented

Industry news, News / 19 July 2011 / Janssen Therapeutics

Janssen Therapeutics, presented 96-week findings from two pivotal Phase 3 clinical trials…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...